AUS
NZ
UK
CA
USA
IND
Headlines
- Merck Outpaces AbbVie in Revenue Growth
- Merck's Superior Profitability and Stability in Pharma
Merck (NYSE:MRK) has shown strong gains, with its stock price increasing by 65% from early 2021 to around $115 today. However, AbbVie has outperformed, with a 115% rise over the same period. Despite these gains, both companies saw returns fluctuate significantly in the last three years. While Merck achieved returns of 2% in 2021, 49% in 2022, and 1% in 2023, AbbVie recorded returns of 32%, 24%, and 1% respectively. In contrast, the S&P 500 posted returns of 27%, -19%, and 24% during these years. This indicates that both Merck and AbbVie underperformed the broader market in 2023, highlighting the challenges of consistently surpassing the S&P 500.
Merck's Superior Revenue Growth
Merck's revenue grew at an average annual rate of 13.5%, from $41.5 billion in 2020 to $60.1 billion in 2023. In comparison, AbbVie’s revenue grew at a slower rate of 6.5%, from $45.8 billion to $54.3 billion over the same period. Merck’s growth has been significantly driven by the success of its flagship drug, Keytruda, whose sales surged 74% to $25 billion in 2023. Keytruda’s expanding indications have been key to its success, but it faces future challenges as biosimilars enter the market.
Additionally, Merck’s Gardasil vaccine has seen a substantial increase in sales, rising 126% to $8.9 billion in 2023. Despite anticipated future declines in sales due to market exclusivity loss, Gardasil's impact on Merck's revenue is expected to be less significant than that of Keytruda.
AbbVie’s (NYSE:ABBV) revenue growth has been primarily supported by its acquisition of Allergan and the sales of its new drugs, Skyrizi and Rinvoq. However, the company faces a significant revenue decline in its blockbuster drug, Humira, due to biosimilar competition. Although AbbVie’s newer drugs show promise, the loss of Humira's market share presents a considerable challenge.
Profitability and Financial Stability
Merck’s operating margin fell from 13.4% in 2020 to 4.9% in 2023, largely due to acquisition-related charges. However, over the last twelve months, Merck's operating margin stood at 25.7%, outperforming AbbVie’s 24.9%.
Financially, Merck demonstrates greater stability, with a lower debt-to-equity ratio of 13% compared to AbbVie’s 21%. Additionally, Merck’s higher cash percentage of assets suggests a stronger financial cushion.
